← Back to patent-cliff list
EP-547
Tier C — Watch / tradeEP-547
Escient Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MRGPRX4
Indications (approved)：Pruritus, 胆汁淤积, Renal impairment
Regional status
US
Discontinued
2022-10-06
EU
Phase II
2022-10-06
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of EP-547?
Approved indications include: Pruritus, 胆汁淤积, Renal impairment.
When does the EP-547 patent expire?
No public expiry year is available for EP-547 yet; this page updates once verified.
How do I get a quote for EP-547 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05